A panelist discusses how polycythemia vera (PV) is a uncommon myeloproliferative neoplasm (MPN) characterised by extreme crimson blood cell manufacturing, primarily affecting older adults with JAK2 mutations, and whereas it may be managed with therapy, sufferers face elevated dangers of blood clots and potential development to extra critical circumstances.
